Key facts
- This page summarizes Briggs Morrison's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jul 2022, 16:09.
Briggs Morrison - 01 Jul 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)
- Reporting relationship
- President, Head of R&D, Director
- Issuer ticker
- SNDX
- Reported as of
- 01 Jul 2022
- Net transaction value
- -$734,927
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2022, 16:09:46 UTC
- Prior SEC filing
- 21 Jun 2022
- Next SEC filing
- 16 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael A. Metzger, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Briggs Morrison filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 05 Jul 2022.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: -$734,927.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SNDX
transaction
Common Stock
Options Exercise
- Transaction value
- $448,502
- Shares
- +62,292
- Change %
- +349%
- Price
- $7.20
- Shares after
- 80,128
- Date
- 01 Jul 2022
- Ownership
- Direct
SNDX
transaction
Common Stock
Sale
- Transaction value
- $1,183,430
- Shares
- -62,292
- Change %
- -78%
- Price
- $19.00
- Shares after
- 17,836
- Date
- 01 Jul 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNDX
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -62,292
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 62,292
- Exercise price
- $7.20
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,200,616 options to purchase shares of common stock that are vested and immediately exercisable and a total of 397,792 options to purchase shares of common stock that have not yet vested.
Footnote F2
The sale prices ranged from $18.61 to $19.38
Footnote F3
This option is fully vested.